Literature DB >> 25331178

Gastrointestinal cancer: FOLFIRI-improving toxicity in first-line treatment of advanced gastric cancer.

Alessia Errico.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25331178     DOI: 10.1038/nrclinonc.2014.184

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.

Authors:  Rosine Guimbaud; Christophe Louvet; Pauline Ries; Marc Ychou; Emilie Maillard; Thierry André; Jean-Marc Gornet; Thomas Aparicio; Suzanne Nguyen; Ahmed Azzedine; Pierre-Luc Etienne; Eveline Boucher; Christine Rebischung; Pascal Hammel; Philippe Rougier; Laurent Bedenne; Olivier Bouché
Journal:  J Clin Oncol       Date:  2014-10-06       Impact factor: 44.544

  1 in total
  1 in total

1.  XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).

Authors:  Xiao-Dong Zhu; Ming-Zhu Huang; Yu-Sheng Wang; Wan-Jing Feng; Zhi-Yu Chen; Yi-Fu He; Xiao-Wei Zhang; Xin Liu; Chen-Chen Wang; Wen Zhang; Jie-Er Ying; Jun Wu; Lei Yang; Yan-Ru Qin; Jian-Feng Luo; Xiao-Ying Zhao; Wen-Hua Li; Zhe Zhang; Li-Xin Qiu; Qi-Rong Geng; Jian-Ling Zou; Jie-Yun Zhang; Hong Zheng; Xue-Feng Song; Shu-Sheng Wu; Cheng-Yan Zhang; Zhe Gong; Qin-Qin Liu; Xiao-Feng Wang; Qi Xu; Qi Wang; Jian-Mei Ji; Jian Zhao; Wei-Jian Guo
Journal:  Cancer Commun (Lond)       Date:  2022-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.